- Home
- LIEN vs ITOS Comparison
LIEN vs ITOS Comparison
Compare LIEN & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- ITOS
- Stock Information
- Founded
- LIEN 2021
- ITOS 2011
- Country
- LIEN United States
- ITOS United States
- Employees
- LIEN N/A
- ITOS N/A
- Industry
- LIEN
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LIEN
- ITOS Health Care
- Exchange
- LIEN NYSE
- ITOS Nasdaq
- Market Cap
- LIEN 234.6M
- ITOS 381.2M
- IPO Year
- LIEN 2022
- ITOS 2020
- Fundamental
- Price
- LIEN $10.22
- ITOS $10.18
- Analyst Decision
- LIEN Buy
- ITOS Hold
- Analyst Count
- LIEN 2
- ITOS 6
- Target Price
- LIEN N/A
- ITOS $10.60
- AVG Volume (30 Days)
- LIEN 62.6K
- ITOS 911.5K
- Earning Date
- LIEN 08-07-2025
- ITOS 08-07-2025
- Dividend Yield
- LIEN 13.31%
- ITOS N/A
- EPS Growth
- LIEN 30.25
- ITOS N/A
- EPS
- LIEN 1.15
- ITOS N/A
- Revenue
- LIEN $30,828,508.00
- ITOS $35,000,000.00
- Revenue This Year
- LIEN $154.46
- ITOS N/A
- Revenue Next Year
- LIEN $10.64
- ITOS N/A
- P/E Ratio
- LIEN $8.86
- ITOS N/A
- Revenue Growth
- LIEN 151.96
- ITOS 177.89
- 52 Week Low
- LIEN $9.70
- ITOS $4.80
- 52 Week High
- LIEN $13.38
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- ITOS 67.13
- Support Level
- LIEN N/A
- ITOS $9.95
- Resistance Level
- LIEN N/A
- ITOS $10.19
- Average True Range (ATR)
- LIEN 0.00
- ITOS 0.15
- MACD
- LIEN 0.00
- ITOS -0.09
- Stochastic Oscillator
- LIEN 0.00
- ITOS 84.75
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.